Description

OVA-E1 peptide, is an antagonist variant of SIINFEKL [OVA (257-264). OVA-E1 peptide, activates the p38 and JNK cascades similarly in mutant and wild-type thymocytes[1].—COVID-19-immunoregulation–C47H76N10O14—-[1]Leandro J Carreño, et al. The Half-Life of the T-cell receptor/peptide-major Histocompatibility Complex Interaction Can Modulate T-cell Activation in Response to Bacterial Challenge. Immunology. 2007 Jun;121(2):227-37.–153316-01-9–1005.16—-O=C(N[C@@H]([C@@H](C)CC)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC(N)=O)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCCCN)C(N[C@@H](CC(C)C)C(O)=O)=O)=O)=O)=O)=O)=O)[C@H](CCC(O)=O)N–Inflammation/Immunology–H2O–JNK;p38 MAPK—-MAPK/ERK Pathway–Peptides